From GlobeNewswire: 2025-01-13 02:08:00

Telix Pharmaceuticals reports Q4 2024 revenue of approximately US$142 million, representing a 46% increase over the previous year. Full-year revenue for 2024 exceeds guidance at approximately US$517 million, a 55% increase over 2023. The company plans to provide guidance for FY2025 when reporting audited annual results on February 20, 2025.

In Q4 2024, Telix made significant progress in its therapeutics business, advancing clinical trials for prostate, kidney, and glioblastoma cancer therapies. The company also acquired FAP-targeting assets for bladder cancer treatment and entered into a partnership for next-generation therapeutic candidates. Telix is focused on innovative radiopharmaceuticals to address unmet medical needs in oncology.

Telix submitted a Biologics License Application for kidney cancer imaging and received FDA acceptance for its brain cancer imaging candidate. Global regulatory submissions for Illuccix are pending decisions in various countries. The company also announced a partnership with Subtle Medical for AI-powered PET imaging and the transfer of marketing rights for Scintimun.

Telix’s manufacturing solutions saw progress with the acquisition of RLS (USA) Inc and the completion of a production facility buildout in Brussels. The company’s American Depository Shares began trading on the Nasdaq in November 2024. Telix is headquartered in Melbourne, Australia, with operations in the US, Europe, Canada, and Japan, focusing on therapeutic and diagnostic radiopharmaceuticals.



Read more at GlobeNewswire:: Telix Exceeds FY24 Guidance with US$142M Q4 Revenue